# Nivolumab and 177Lu-DOTA0-Tyr3-Octreotate for Patients With Extensive-Stage Small Cell Lung Cancer

> **NCT03325816** · PHASE1,PHASE2 · COMPLETED · sponsor: **Georgetown University** · enrollment: 9 (actual)

## Conditions studied

- Small Cell Lung Cancer
- Small Cell Lung Cancer Extensive Stage

## Interventions

- **DRUG:** Nivolumab
- **RADIATION:** 177Lu-DOTA0-Tyr3-Octreotate

## Key facts

- **NCT ID:** NCT03325816
- **Lead sponsor:** Georgetown University
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-11-20
- **Primary completion:** 2019-03-28
- **Final completion:** 2020-08-11
- **Target enrollment:** 9 (ACTUAL)
- **Last updated:** 2021-03-16

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03325816

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03325816, "Nivolumab and 177Lu-DOTA0-Tyr3-Octreotate for Patients With Extensive-Stage Small Cell Lung Cancer". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT03325816. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*